David Warshal
Head, Division of Gynecologic Oncology
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
David Warshal is the Head of the Division of Gynecologic Oncology at Cooper University Health Care, USA. His research areas include cervical cancer, endometrial carcinoma, and ovarian cancer, focusing on surgical therapies, quality of life evaluations, and innovative treatments such as gene therapy. He has contributed to various studies assessing patient outcomes and molecular classifications in relation to cancer treatments.
Articles (10)
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
High mortality rates in ovarian cancer have been linked to recurrence, metastasis, and chemoresistant disease, which are known to involve not only genetic changes but also epigenetic aberrations. In ovarian cancer, adipose-derived stem cells from the omentum (O-ASCs) play a crucial role in supporting the tumor and its tumorigenic microenvironment, further propagating epigenetic abnormalities and dissemination of the disease. Epigallocatechin gallate (EGCG), a DNA methyltransferase inhibitor derived from green tea, and Indole-3-carbinol (I3C), a histone deacetylase inhibitor from cruciferous vegetables, carry promising effects in reprograming aberrant epigenetic modifications in cancer. Therefore, we demonstrate the action of these diet-derived compounds in suppressing the growth of 3D ovarian cancer spheroids or organoids as well as post-treatment cancer recovery through proliferation, migration, invasion, and colony formation assays when compared to the synthetic epigenetic compound Panobinostat with or without standard chemotherapy. Finally, given the regulatory role of the secretome in growth, metastasis, chemoresistance, and relapse of disease, we demonstrate that natural epigenetic compounds can regulate the secretion of protumorigenic growth factors, cytokines, extracellular matrix components, and immunoregulatory markers in human ovarian cancer specimens. While further studies are needed, our results suggest that these treatments could be considered in the future as adjuncts to standard chemotherapy, improving efficiency and patient outcomes.
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2021
Collaborators (3)
Debra Richardson
Professor and Section Chief
University of Kansas Cancer Center
Shuyue Ren
-
Olga Ostrovsky
Cooper Medical School of Rowan University
Make your next move.
Prepare your application
Review drafts before you send them.